Standard and competing risk analysis of the effect of albuminuria on cardiovascular and cancer mortality in patients with type 2 diabetes mellitus

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA. 1958;53:457–81.

Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187–220.

Verduijn M, Grootendorst DC, Dekker FW, Jager KJ, le Cessie S. The analysis of competing events like cause-specific mortality—beware of the Kaplan-Meier method. Nephrol Dial Transpl. 2011;26:56–61.

Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.

Messerli FH, Bangalore S, Torp-Pedersen C, Staessen JA, Kostis JB. Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d’Alembert. Eur Heart J. 2013;34:1095–8.

Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51:524–32.

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA. 1999;94:496–509.

Health & Social Care Information Centre. National Diabetes Audit 2013-2014 and 2014-2015. Report 1: Care processes and treatment targets. London: Health and Social Care Information Centre; 2016.

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S5–20.

Thunander M, Petersson C, Jonzon K, Fornander J, Ossiansson B, Torn C, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diab Res Clin Pr. 2008;82:247–55.

Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, et al. Association of Glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.

KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:136–50.

Adler AI, Stevens RJ, Manley SE, Bilous RW, C a C, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–32.

Gerstein HC, Hoogwerf B, Rashkow A. Albuminuria and risk of cardiovascular events, death, and heart failure. JAMA. 2001;286:421–6.

Taylor KS, Heneghan CJ, Farmer AJ, Fuller AM, Adler AI, Aronson JK, et al. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013;36:2366–71.

Jørgensen L, Heuch I, Jenssen T, Jacobsen BK. Association of albuminuria and cancer incidence. J Am Soc Nephrol. 2008;19:992–8.

Szablewski L. Diabetes mellitus: influences on cancer risk. Diabetes Metab Res Rev. 2014;30:543–53.

Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44:827–36.

Student. The probable error of a mean. Biometrika. 1908;6:1–25.

Fisher RA. On the interpretation of χ 2 from contingency tables, and the calculation of P. J R Stat Soc. 1922;85:87–94.

Bonferroni CE. Teoria Statistica delle Classi e Calcolo delle Probabilità. Firenzi: R Istituto Superiore di Scienze Economiche e Commerciali di Firenze; 1936.

Dunn OJ. Estimation of the medians for dependent variables. Ann Math Stat. 1959;30:192–7.

Dunn OJ. Multiple comparisons among means. JASA. 1961;56:52–64.

Mantel N. Evaluation of survival data and two new rank-order statistics arising in its consideration. Cancer Chemo Rep. 1966;50:163–70.

Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. JASA. 1963;58:690–700.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

Savage IR. Contributions to the theory of rank-order statistics - the two-sample case. Ann Math Stat. 1956;27:590–615.

Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–54.

Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170:244–56.

Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transpl. 2013;28:2670–7.

Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–26.

Zhou B, Fine JP, Laird G. Goodness-of-fit test for proportional subdistribution hazards model. Stat Med. 2013;32:3804–11.

Feakins BG. Competing risks methodology in the evaluation of cardiovascular and cancer mortality as a consequence of albuminuria in type 2 diabetes. Oxford: University of Oxford; 2016.

Wong G, Zoungas S, Lo S, Chalmers J, Cass A, Neal B, et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrol Dial Transpl. 2012;27:3337–44.

Southern DA, Faris PD, Brant R, Galbraith PD, Norris CM, Knudtson ML, et al. Kaplan-Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol. 2006;59:1110–4.

Feinstein M, Ning H, Kang J, Bertoni A, Carnethon M, Lloyd-Jones DM. Racial differences in risks for first cardiovascular events and noncardiovascular death: the atherosclerosis risk in communities study, the cardiovascular health study, and the multi-ethnic study of atherosclerosis. Circulation. 2012;126:50–9.

Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Doi M, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation. 2009;119:2136–45.

Hsu JY, Roy JA, Xie D, Yang W, Shou H, Anderson AH, et al. Statistical methods for cohort studies of CKD: survival analysis in the setting of competing risks. Clin J Am Soc Nephrol. 2017;12:1181–9.

Deslandes E, Chevret S. Joint modeling of multivariate longitudinal data and the dropout process in a competing risk setting: application to ICU data. BMC Med Res Methodol. 2010;10:69.

Yu T-Y, Li H-Y, Jiang Y-D, Chang T-J, Wei J-N, Lin C-M, et al. Serum vascular adhesion protein-1 level predicts risk of incident cancers in subjects with type II diabetes. Cancer Epidemiol Biomark Prev. 2014;23:1366–73.

Haller B, Schmidt G, Ulm K. Applying competing risks regression models: an overview. Lifetime Data Anal. 2013;19:33–58.

Latouche A, Boisson V, Chevret S, Porcher R. Misspecified regression model for the subdistribution hazard of a competing risk. Stat Med. 2007;26:965–74.

Wolbers M, Koller MT, Witteman JCM, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009;20:555–61.

Lim HJ, Zhang X, Dyck R, Osgood N. Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes. BMC Med Res Methodol. 2010;10:97.

Klein JP, Andersen PK. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics. 2005;61:223–9.

Scheike TH, Zhang M-J, Gerds TA. Predicting cumulative incidence probability by direct binomial regression. Biometrika. 2008;95:205–20.

Checkley W, Brower RG, Muñoz A. Inference for mutually exclusive competing events through a mixture of generalized gamma distributions. Epidemiology. 2010;21:557–65.

Sen A, Banerjee M, Li Y, Noone AM. A Bayesian approach to competing risks analysis with masked cause of death. Stat Med. 2010;29:1681–95.